Abstract：
:The costs of developing and producing new-generation vaccines have increased compared to many of the older, "traditional" vaccines because of new technologies and regulatory requirements. While the public sector often supports basic research costs, private manufacturers are usually responsible for the investments in product development and production scale-up. When considering investments, firms evaluate the probability of a market. Unfortunately, the developing country vaccine market is small (in revenue terms) and often unpredictable, particularly given inaccurate forecasting in the past. Low-income developing countries expect low prices. Demand (actual decisions to pay for and introduce the vaccine) is almost always lower than need (estimates of requirements to achieve optimal public health outcomes), a distinction that may be even more significant for HPV vaccines given the number of new vaccines against priority diseases that will become available over the coming 5 years. One new mechanism under consideration to address some of these challenges is Advanced Market Commitments (AMCs). By providing an assured price subsidy for developing country purchase of a future vaccine meeting predefined standards, an AMC would provide industry with greater assurances of earning a reasonable return on their investment to serve the poorest developing countries. The AMC mechanism could provide critical motivation for increased industry (private) investment that would otherwise not occur. HPV vaccines are one of six vaccines being considered for a possible AMC pilot.
journal_name
Vaccinejournal_title
Vaccineauthors
Batson A,Meheus F,Brooke Sdoi
10.1016/j.vaccine.2006.05.042subject
Has Abstractpub_date
2006-08-31 00:00:00pages
S3/219-25eissn
0264-410Xissn
1873-2518pii
S0264-410X(06)00592-5journal_volume
24 Suppl 3pub_type
杂志文章,评审相关文献
VACCINE文献大全abstract：:The hepatitis E virus (HEV) vaccine, Hecolin(®), was licensed in China for the prevention of HEV infection and HEV-related diseases with demonstrated safety and efficacy [1,2]. The vaccine is composed of a truncated HEV capsid protein, p239, as the sole antigen encoded by open reading frame 2 and produced using Escher...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2014.05.064
更新日期：2014-07-07 00:00:00
abstract：:Obesity is a risk factor for complicated influenza A/H1N1 disease and poor vaccine immunogenicity. Leptin, an adipocyte-derived hormone/cytokine, has many immune regulatory functions and therefore could explain susceptibility to infections and poor vaccine outcomes. We recruited 159 healthy adults (50-74 years old) wh...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2013.12.009
更新日期：2014-02-07 00:00:00
abstract：:CIMAvax-EGF consists of a human recombinant epidermal growth factor (EGF), coupled to P64k, a recombinant carrier protein from N. meningitis, and Montanide ISA 51 as adjuvant. The vaccine immunization induces a specific antibody production, inhibiting the EGF/EGF-R interaction through EGF deprivation. The objective of...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2012.01.092
更新日期：2012-05-09 00:00:00
abstract：:The overall burden of illness from diseases for which vaccines are available disproportionately falls on adults. Adults are recommended to receive vaccinations based on their age, underlying medical conditions, lifestyle, prior vaccinations, and other considerations. Updated vaccine recommendations from CDC are publis...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2015.09.054
更新日期：2015-11-27 00:00:00
abstract：:Influenza virus hemagglutinin (HA) and neuraminidase (NA) proteins elicit protective antibody responses and therefore, are used as targets for vaccination, especially the HA protein. However, these proteins are subject to antigenic drift, decreasing vaccine efficacy, and few to no studies have analyzed antigenic varia...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2018.09.005
更新日期：2018-10-15 00:00:00
abstract：:The pandemic of HIV-1 has continued for decades, yet there remains no licensed vaccine. Previous research has demonstrated the effectiveness of a multi-envelope, multi-vectored HIV-1 vaccine in a macaque-SHIV model, illustrating a potential means of combating HIV-1. Specifically, recombinant DNA, vaccinia virus (VV) a...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2012.03.001
更新日期：2012-05-02 00:00:00
abstract：BACKGROUND:BCR/ABL and Wilms' tumor 1 (WT1) are an ideal tumor associated antigens which can be used to develop a potential chronic myeloid leukemia (CML) dentritic cell (DC) vaccine. Here, we constructed a novel polyepitope vaccine which used recombinant lentiviral vector carrying BCR/ABL and WT1 genes, and determined...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2014.04.041
更新日期：2014-06-12 00:00:00
abstract：:Dengue is a major infectious disease that affects people living in tropical and subtropical regions around the world. The causative agents are dengue virus serotype 1, 2, 3, and 4 (DENV1, 2, 3, and 4). Developing a vaccine for dengue is a high priority for public health, but traditional methods have faced numerous obs...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2014.03.091
更新日期：2014-06-24 00:00:00
abstract：:Sip is a surface-exposed protein of GBS, which causes severe neonatal disease. Because Sip elicits a protective immune response in mice, we assessed whether pregnant women and newborns have Sip antibodies. Sera were collected from 644 pregnant women and 176 of their healthy newborns, and 10 newborns with GBS disease a...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2006.06.020
更新日期：2006-11-17 00:00:00
abstract：:Immunologic tolerance to endogenous antigens reduces antitumor responses. Gp70 is an endogenous tumor-associated antigen (TAA) of the BALB/c-derived colon carcinoma CT26. We found that expression of gp70 mRNA is detectable in tissues of mice 8 months of age and older. We showed that expression of gp70 establishes immu...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2008.01.052
更新日期：2008-03-28 00:00:00
abstract：:Organised and quality assured cytology-based screening programmes have substantially reduced cervical cancer incidence in many developed countries. However, there are considerable barriers to setting up cytology-based screening programs, particularly in developing countries. This has stimulated the search for novel an...
journal_title：Vaccine
pub_type： 杂志文章,评审
doi：10.1016/j.vaccine.2006.05.121
更新日期：2006-08-31 00:00:00
abstract：:We recently reported that administration of low doses of myotoxins at vaccination sites potentiated antigen-specific T-cell immunity induced by genetic cancer vaccines in mice, an effect which was superior to TLR agonists. In the current study, we found unexpectedly that the mechanism of this potent adjuvant effect wa...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2010.09.084
更新日期：2010-11-23 00:00:00
abstract：:Genetically modified bacterial flagellin (Fla), a Toll-like receptor-5 (TLR5) ligand, was evaluated as a fusion partner for human papillomavirus (HPV) L2-based immunogens in two animal challenge models; either cutaneous inoculation of rabbits with HPV 'quasivirions' containing cottontail rabbit papillomavirus (CRPV) g...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2014.04.032
更新日期：2014-06-12 00:00:00
abstract：OBJECTIVE:We related seroprevalence and outbreaks data in order to identify factors that could explain the occurrence of outbreaks despite high vaccination coverage in Medellín Colombia. METHODS:Samples from a population seroprevalence data obtained in 2009 in a random survey were analyzed. IgG levels were determined ...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2015.08.088
更新日期：2015-10-13 00:00:00
abstract：BACKGROUND:A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RotaTeq™, RV5) against rotavirus gastroenteritis (RVGE). METHODS:4040 participants aged 6-12weeks were...
journal_title：Vaccine
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1016/j.vaccine.2017.08.081
更新日期：2017-10-13 00:00:00
abstract：:In a phase I/II dose escalation study, varying volumes (0.1 ml, 0.5 ml, 1.0 ml and 2.0 ml) of 7-valent pneumococcal conjugate vaccine (PCV) (Prevnar or 0.5 ml of 23-valent pneumococcal polysaccharide vaccine (PPV) were administered to 220 adults 70 through 79 years of age previously vaccinated with 0.5 ml PPV at age 6...
journal_title：Vaccine
pub_type： 临床试验,杂志文章
doi：10.1016/j.vaccine.2005.02.017
更新日期：2005-05-25 00:00:00
abstract：:Based on studies on the genetic and molecular basis of Shigella flexneri invasive properties, we have constructed and evaluated a double mutant of S. flexneri serotype 5 for utilization as a live attenuated oral vaccine against shigellosis. The first mutation, icsA, blocks intracellular spread of bacteria as well as c...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/0264-410x(89)90160-6
更新日期：1989-10-01 00:00:00
abstract：:The immunity levels against diphtheria, tetanus and poliomyelitis were investigated among blood donors (n = 2079) in Berlin. Of all participants, only 60% had full, long-term protection against diphtheria, 72% against tetanus, 87% against poliomyelitis type 1, 77% against poliomyelitis type 2 and 73% against type 3. T...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/s0264-410x(98)00269-2
更新日期：1999-02-26 00:00:00
abstract：INTRODUCTION:This study aimed to develop and undertake a preliminary validation of a French Survey Questionnaire for the Determinants of HPV Vaccine Hesitancy (FSQD-HPVH). METHODS:We undertook an electronic-based Delphi consultation among a panel of Francophone experts in two rounds. Round 1 consisted of the assessmen...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2020.07.027
更新日期：2020-09-03 00:00:00
abstract：:At the present time it is estimated that the process of development of a vaccine from discovery to licensure takes approximately 18-20 years and costs in excess of US$500 million. For "routine" vaccines, the case for developing a vaccine is straightforward in terms of economics and large scale public health utilizatio...
journal_title：Vaccine
pub_type： 杂志文章,评审
doi：10.1016/j.vaccine.2009.07.094
更新日期：2009-11-05 00:00:00
abstract：:A WHO workshop organized following the 2009 H1N1 pandemic recommended development of alternative influenza vaccine potency assays as high priority that could expedite the release of vaccine lots in the face of future influenza pandemics. We have developed an antibody independent, simple, high throughput receptor-bindi...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2014.02.049
更新日期：2014-04-17 00:00:00
abstract：OBJECTIVES:Using dynamic transmission models we evaluated the health and cost outcomes of adding acellular pertussis (aP) vaccination of pregnant women to infant vaccination in three Brazilian states that represent different socioeconomic conditions. The primary objective was to determine whether the same model structu...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2020.09.008
更新日期：2021-01-03 00:00:00
abstract：:Liposome and cholera toxin (CT) are considered to be effective antigen delivery vehicles and adjuvants for mucosal vaccines. The effect of these antigen delivery systems on adjuvant responses to mucosally administered pneumococcal polysaccharide (Pnup) was investigated in this study. Both mucosal (e.g. oral) and syste...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/0264-410x(95)00198-a
更新日期：1996-04-01 00:00:00
abstract：:Pneumococcal and Salmonella typhi infections are two major diseases for children in developing countries. For typhoid fever, licensed Vi polysaccharide vaccines are ineffective in children <2-year old. While investigational Vi conjugate vaccines have been shown effective in clinical trials, they are currently only ava...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2012.03.039
更新日期：2012-05-14 00:00:00
abstract：:Measles, mumps and rubella (MMR) vaccination coverage in Italy has been decreasing starting from 2012 and, at the present, none of the Italian regions has achieved the goal of 95% coverage target. A decision of the Court of Justice of Rimini in March 2012 that awarded vaccine-injury compensation for a case of autism h...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2017.07.029
更新日期：2017-08-16 00:00:00
abstract：:Although vaccination against Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae type b (Hib) is recommended for immunocompromised patients, such as patients with B-cell chronic lymphocytic leukaemia (B-CLL), its protective effect is questionable. We studied antibody responses to pneumococcal polysacch...
journal_title：Vaccine
pub_type： 临床试验,杂志文章
doi：10.1016/s0264-410x(00)00409-6
更新日期：2001-02-08 00:00:00
abstract：:Inactivated porcine parvovirus (PPV) vaccines are available commercially and widely used in the breeding herds. However, inactivated PPV vaccines have deficiencies in induction of specific cellular immune response. Transfer factor (TF) is a material that obtained from the leukocytes, and is a novel immune-stimulatory ...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2012.05.077
更新日期：2012-07-27 00:00:00
abstract：:This study was designed to evaluate the immunogenicity of autoclaved and nonautoclaved preparations of a vaccine composed of whole antigens from killed promastigotes of Leishmania amazonensis. Leishmanin skin-test (LST)-negative volunteers were immunized with either autoclaved or nonautoclaved vaccine preparations (32...
journal_title：Vaccine
pub_type： 临床试验,杂志文章
doi：10.1016/s0264-410x(98)00338-7
更新日期：1999-03-05 00:00:00
abstract：BACKGROUND:Lifetime protection against pertussis has been adopted as a goal of immunization programs in Canada. To anticipate adult coverage with a combined product containing tetanus (T) and diphtheria (d) toxoids and acellular pertussis (aP) vaccine as a booster dose, we conducted a survey of households in British Co...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2004.05.033
更新日期：2004-12-02 00:00:00
abstract：:Safety of individuals at risk of immune suppression is an important concern for live vaccines. The new-generation tuberculosis vaccine candidate MTBVAC, a genetically engineered doubly attenuated Mycobacterium tuberculosis mutant with deletions in phoP and fadD26 virulence genes has demonstrated comparable safety in d...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2014.07.047
更新日期：2014-09-08 00:00:00
